Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Making Sense of Antisense Oligonucleotides: A Narrative Review.

Goyal N, Narayanaswami P.

Muscle Nerve. 2017 Nov 3. doi: 10.1002/mus.26001. [Epub ahead of print] Review.

PMID:
29105153
2.

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.

Nguyen Q, Yokota T.

J Pers Med. 2017 Oct 16;7(4). pii: E13. doi: 10.3390/jpm7040013. Review.

3.

[Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].

Dal-RĂ© R, Lopez de Munain A, Ayuso C.

Rev Neurol. 2017 Oct 16;65(8):373-380. Review. Spanish.

4.
5.

FDA-Approved Oligonucleotide Therapies in 2017.

Stein CA, Castanotto D.

Mol Ther. 2017 May 3;25(5):1069-1075. doi: 10.1016/j.ymthe.2017.03.023. Epub 2017 Mar 31. Review.

PMID:
28366767
6.

Eteplirsen in the treatment of Duchenne muscular dystrophy.

Lim KR, Maruyama R, Yokota T.

Drug Des Devel Ther. 2017 Feb 28;11:533-545. doi: 10.2147/DDDT.S97635. eCollection 2017. Review.

7.

2'-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping.

Lee T, Awano H, Yagi M, Matsumoto M, Watanabe N, Goda R, Koizumi M, Takeshima Y, Matsuo M.

Genes (Basel). 2017 Feb 10;8(2). pii: E67. doi: 10.3390/genes8020067. Review.

8.

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.

Reinig AM, Mirzaei S, Berlau DJ.

Pharmacotherapy. 2017 Apr;37(4):492-499. doi: 10.1002/phar.1909. Epub 2017 Mar 10. Review.

PMID:
28152217
9.

Exon skipping: a first in class strategy for Duchenne muscular dystrophy.

Niks EH, Aartsma-Rus A.

Expert Opin Biol Ther. 2017 Feb;17(2):225-236. doi: 10.1080/14712598.2017.1271872. Epub 2016 Dec 23. Review.

PMID:
27936976
10.

Eteplirsen: First Global Approval.

Syed YY.

Drugs. 2016 Nov;76(17):1699-1704. Review.

PMID:
27807823
11.

Eteplirsen (Exondys 51) for duchenne muscular dystrophy.

[No authors listed]

Med Lett Drugs Ther. 2016 Nov 7;58(1507):145-146. Review. No abstract available.

PMID:
27805575
12.

Pharmacology of Antisense Drugs.

Bennett CF, Baker BF, Pham N, Swayze E, Geary RS.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105. doi: 10.1146/annurev-pharmtox-010716-104846. Epub 2016 Oct 10. Review.

PMID:
27732800
13.

Exon skipping therapy for Duchenne muscular dystrophy.

Kole R, Krieg AM.

Adv Drug Deliv Rev. 2015 Jun 29;87:104-7. doi: 10.1016/j.addr.2015.05.008. Epub 2015 May 14. Review.

PMID:
25980936
14.

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Ruegg UT.

Curr Opin Neurol. 2013 Oct;26(5):577-84. doi: 10.1097/WCO.0b013e328364fbaf. Review.

PMID:
23995279

Supplemental Content

Loading ...
Support Center